These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35209779)

  • 1. A modern approach to glucose-lowering therapy in frail older people with type 2 diabetes mellitus.
    Abdelhafiz AH; Pennells D; Sinclair AJ
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):95-98. PubMed ID: 35209779
    [No Abstract]   [Full Text] [Related]  

  • 2. Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people.
    Emmerton D; Abdelhafiz A
    Hosp Pract (1995); 2021 Aug; 49(3):164-175. PubMed ID: 33729898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P; Bouma A; Landman GW; Groenier KH; Bilo H; Kleefstra N; van Hateren KJ
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract]   [Full Text] [Related]  

  • 4. [In the elderly avoidance of hypoglycemia is in the foreground].
    Kern W
    MMW Fortschr Med; 2014 Nov; 156(19):49-50, 52-3. PubMed ID: 25510024
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.
    Marrs JC
    Drugs Aging; 2012 May; 29(5):e1-e12. PubMed ID: 22530704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis on the Efficacy of Novel Glucose-Lowering Agents in Older Patients With Type 2 Diabetes Mellitus.
    Ahmed A; Imran L; Naeem U; Jawed A; Jawed A; Khan Z; Arshad AR; Arshad MS
    Am J Cardiol; 2023 Jan; 187():127-130. PubMed ID: 36459735
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.
    Bakris G
    J Fam Pract; 2019 Oct; 68(8):S1-S6. PubMed ID: 31697796
    [No Abstract]   [Full Text] [Related]  

  • 8. Frailty and safety: the example of diabetes.
    Abbatecola AM; Olivieri F; Corsonello A; Strollo F; Fumagalli A; Lattanzio F
    Drug Saf; 2012 Jan; 35 Suppl 1():63-71. PubMed ID: 23446787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of new antidiabetics in the elderly population].
    Besse S; Besse A; Jornayvaz FR
    Rev Med Suisse; 2016 Jun; 12(521):1101-6. PubMed ID: 27487679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goals of glycemic control in frail older patients with diabetes.
    Lee SJ; Eng C
    JAMA; 2011 Apr; 305(13):1350-1. PubMed ID: 21467289
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes: intensive glucose-lowering therapy-weighing up the evidence.
    Cohen N
    Nat Rev Endocrinol; 2010 Jan; 6(1):9-10. PubMed ID: 20010962
    [No Abstract]   [Full Text] [Related]  

  • 14. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetes mellitus in the elderly].
    van der Veen EA
    Tijdschr Gerontol Geriatr; 1990 Feb; 21(1):7-10. PubMed ID: 2180142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic oral treatment in older people: does frailty matter?
    Abbatecola AM; Paolisso G; Corsonello A; Bustacchini S; Lattanzio F
    Drugs Aging; 2009 Dec; 26 Suppl 1():53-62. PubMed ID: 20136169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
    Mennecart M; Mondon K; Malherbe C; Constans T
    J Am Geriatr Soc; 2014 Dec; 62(12):2460-2. PubMed ID: 25516054
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid improvement of psoriasis in diabetes subsequent to glucose lowering.
    Ogoshi M; Horikawa T
    Int J Dermatol; 2014 Feb; 53(2):e106-7. PubMed ID: 23432425
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial.
    Sinclair AJ; Heller SR; Pratley RE; Duan R; Heine RJ; Festa A; Kiljański J
    Diabetes Obes Metab; 2020 Aug; 22(8):1231-1242. PubMed ID: 32100382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.